Delivery Order SPE2DB20D3103-SPE2DB22FM4Y1
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, with a ceiling value of $2,492.06, is for the delivery of Visipaque 320 mg/ml infusion bottles, a medical product used in healthcare settings. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc.,...
- This federal contract award, valued at $16,457.29, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp. The contract is for the delivery of Visipaque 320 mg/ml bottle 100ml, a medical supply, with a completion date of November 30, 2023. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, valued at $999,999,999 and running through November 2026. The IDC...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of Visipaque 320 mg/ml Bottle 500ml, a medical imaging product, to the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $2,926.84, is a Firm Fixed Price Delivery Order awarded under an Indefinite Delivery Contract (IDC) with the DLA. The IDC, valued up to $999,999,999.00, serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,006.70 firm fixed-price delivery order is for the supply of VISIPAQUE 320 MG/ML BOTTLE 100ML, a medical product. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive...
- This federal contract award, valued at $1,128.44, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of VISIPAQUE 320 MG/ML INFUS BTL 150ML, a medical product, with a performance period ending on May 21, 2025. This delivery order contract is a firm fixed-price type and is not set aside for any specific business category. Amerisourcebergen Drug Corp holds a...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,929.53, is for the delivery of VISIPAQUE 320 MG/ML INFUS BTL 150ML, a medical product. The contract is a Firm Fixed Price Delivery Order with a performance period ending on March 31, 2025. This contract award is associated with a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen...
- This federal contract award, with a value of $2,503.35, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for VISIPAQUE 320 MG/ML BOTTLE 100ML, a medical product, with a completion date of March 5, 2025. The contract has a Firm Fixed Price pricing type and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp has a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $2,845.73 Firm Fixed Price Delivery Order is for the supply of VISIPAQUE 320 MG/ML BOTTLE 100ML, a medical product, to support military treatment facilities and programs. The contract has an ultimate completion date of August 15, 2024 and was awarded on August 14, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between...
- This federal contract award, valued at $2,089.97, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the delivery of VISIPAQUE 320 MG/ML BOTTLE 100ML medical supplies. The contract has a period of performance through January 18, 2024 and is structured as a firm fixed-price delivery order. This award does not have a set-aside designation, indicating open competition. AmerisourceBergen, a major pharmaceutical distributor and healthcare solutions provider, maintains...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Visipaque 320 mg/ml, a pharmaceutical product, with a ceiling value of $26,715.17 and a period of performance through July 3, 2025. The contract is a firm-fixed-price delivery order, without a set-aside designation, indicating open competition. AmerisourceBergen holds a...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB22FM4Y1Delivery Order
This federal contract award, valued at $4,171.20, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Visipaque 320 mg/ml infusion bottles, 150 ml, a specialty pharmaceutical product. The award is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC, valued at up to $999,999,999.00, serves as the primary vehicle for Cencora, Inc. to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. No set-aside designation was used for this contract. The award demonstrates Amerisourcebergen's role as a critical supplier of essential medical commodities to federal agencies, including the Department of Defense and Department of Veterans Affairs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 2/1/22 |